Holen Sie sich die Stockscreener-App
4.21
2.93%
0.12
Handel nachbörslich:
4.20
-0.010
-0.24%
Schlusskurs vom Vortag:
$4.09
Offen:
$4.14
24-Stunden-Volumen:
68,132
Relative Volume:
0.84
Marktkapitalisierung:
$1.28B
Einnahmen:
$842.96M
Nettoeinkommen (Verlust:
$-185.63M
KGV:
-8.0053
EPS:
-0.5259
Netto-Cashflow:
$-228.52M
1W Leistung:
+16.94%
1M Leistung:
+15.98%
6M Leistung:
+15.98%
1J Leistung:
-19.50%
1-Tages-Spanne:
$4.12
$4.22
1-Wochen-Bereich:
$3.47
$4.22
52-Wochen-Spanne:
$2.84
$5.68
Evotec Se Adr Stock (EVO) Company Profile
Vergleichen Sie EVO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EVO
Evotec Se Adr
|
4.21 | 1.28B | 842.96M | -185.63M | -228.52M | -0.5259 |
|
ZTS
Zoetis Inc
|
152.30 | 66.32B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.11 | 46.30B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.31 | 46.11B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
14.72 | 16.87B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
296.42 | 12.79B | 2.76B | 1.11B | 898.10M | 22.77 |
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-07 | Herabstufung | Jefferies | Buy → Hold |
| 2024-08-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-07-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-07-11 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-04-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-01-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-06-23 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-06-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-06-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-04-04 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-12-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-11-16 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-08-10 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2022-03-02 | Fortgesetzt | Cowen | Outperform |
| 2022-01-07 | Fortgesetzt | Citigroup | Neutral |
Alle ansehen
Evotec Se Adr Aktie (EVO) Neueste Nachrichten
Evotec shares surge 51% following InvestingPro’s undervalued signal By Investing.com - Investing.com
Stock Information - Evotec
Evotec SE ADR earnings beat by $0.08, revenue topped estimates - Investing.com Australia
Evotec SE Reports Strong Q4 2024 and New Strategy - TipRanks
Evotec Ag’s Earnings Call: Growth Amid Challenges - TipRanks
Evotec: Management Streamlines Strategy to Refocus on Core Strengths Amid Biologics Momentum - Morningstar
Antibody Discovery Market Size to Achieve USD 22,570 Mn by 2034 | Statifacts - GlobeNewswire Inc.
Evotec: Some Recovery Has Come, But Much More Is Expected - Seeking Alpha
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid - MSN
Markets Brief: Are Bank Stocks Expensive? - Morningstar
Evotec SE withdraws acquisition offer By Investing.com - Investing.com South Africa
Evotec SE withdraws acquisition offer - Investing.com India
Halozyme ends bid to acquire Evotec at €2 billion valuation - Investing.com
Halozyme outlines plan to acquire Evotec for €2 billion - Investing.com
Halozyme outlines plan to acquire Evotec for €2 billion By Investing.com - Investing.com UK
Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says - Yahoo Finance
Evotec SE responds to media speculation - Investing.com India
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion - AOL
Halozyme Therapeutics sinks after confirming $2B Evotec buyout offer - Seeking Alpha
Evotec SE responds to media speculation By Investing.com - Investing.com UK
Halozyme proposes $2 billion acquisition of Evotec - Investing.com India
Earnings call: Evotec SE maintains 2024 outlook amid strategic changes - Investing.com India
Evotec SE ADR earnings beat by $0.02, revenue fell short of estimates - Investing.com
Evotec Reports Strategic Growth Amidst Revenue Challenges - TipRanks
Evotec SE Reports 9M 2024 Results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions - Yahoo Finance
Evotec stock outlook clouded by strategy update delays, warns Jefferies - Investing.com
KZIAKazia Therapeutics Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Annual General Meeting - Evotec
Investor Relations - Evotec
Bristol Myers' German Partner Evotec Plans Layoffs, Cites 'Challenging Revenues, Profitability' - Yahoo Finance
Dozens of US Stocks Are Newly Undervalued After Market Selloff - Morningstar
Evotec shares crash 36% on profit warning - Investing.com
Healthcare Sector - Morningstar
Earnings call: Evotec SE Q1 2024 results show mixed performance amid challenges - Investing.com
T. Rowe Price Raises Stake in Evotec SE - TipRanks
Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J - Yahoo Finance
Finanzdaten der Evotec Se Adr-Aktie (EVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):